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100BACKGROUND & AIMS:reviations used in this pape
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ging.
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The risk of recurrence of Crohn’s disease (CD) from 1 to 10 years after surgery despite initial







109We performed a retrospective study, at 3 inflammatory bowel disease (IBD) centers in France
and Belgium, of all patients with CD (n [ 86) undergoing an ileocecal resection with curative
intent from 2006 through 2016 who did not have endoscopic evidence for recurrence (Rut-
geerts score less than i2) at their baseline assessment. Post-operative recurrence after baseline
endoscopy was defined as a composite endpoint of at least 1 of the following: clinical recur-
rence, IBD-related hospitalization, occurrence of bowel damage, need for endoscopic balloon
dilatation of the anastomosis, and need to repeat the surgery. Risk of mucosal disease pro-
gression was studied as a secondary outcome.r: CD, Crohn’s disease; IBD, inflammatory
rtile range; MRI, magnetic resonance
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184The median time between surgery and baseline endoscopy was 7 months (IQR, 5.7–9.5 months);
40 patients (46.5%) received medical prophylaxis in this period. The median follow-up time
was 3.5 years (IQR, 1.6–5.3 years). Thirty-five patients (40.7%) had a late post-operative
recurrence of CD, with a median time to disease recurrence after baseline endoscopy of 14.2
months (IQR, 6.3–26.1 months). Recurrence status did not differ significantly between patients
with Rutgeerts scores of i0 (20/55) or i1 (15/31) at baseline (P [ .28) and was independent of
medical prophylaxis (16/40 with prophylactic therapy vs 19/46 without prophylactic therapy;
P [ .90). Mucosal disease progressed in 29 of the 71 patients (40.8%) with available data. We
did not identify risk factors for late post-operative recurrence of CD or mucosal disease
progression.185
186CONCLUSIONS:187Among patients with CD treated by ileocecal resection, 40% of patients had a late recurrence,
despite initial endoscopic remission, after a median follow-up time of 3.5 years. Tight moni-











































232Crohn’s disease (CD) is a chronic, disabling in-flammatory bowel disease (IBD).1 Approximately
half of the patients require surgery in the first decade
after diagnosis, and 1 of 3 patients need multiple bowel
resections during their disease course.2 The Rutgeerts
score grades the severity of signs of endoscopic CD
recurrence after ileocecal resection, by focusing on the
mucosa of the ileocolonic anastomosis and the neo-
terminal ileum, just proximal to the anastomosis.3 In a
landmark trial conducted in the prebiologic era, the
Rutgeerts score proved to be the most important vari-
able predicting symptomatic recurrence during follow-
up in postoperative CD patients.4 Nowadays, the score
is well known and widely used to decide about treatment
optimization in clinical practice, and as an endpoint for
grading endoscopic recurrence in clinical trials.
It is recommended to perform ileocolonoscopy within
the first year after surgery because this may affect treat-
ment decisions.5,6 The International Organization for the
study of Inflammatory Bowel Disease agreed that Rutgeerts
score of i0 (no endoscopic lesions) or i1 (between 1 and5
aphthous lesions in the neoterminal ileum) reflects endo-
scopic remission.7 In general, such patients do not require
new therapy, nor intensification of existing therapy.8 Since
most studies in postoperative CD patients aimed to assess
the evolution of patients with Rutgeerts score of i2 or
higher,9,10 little is known about the long-term outcome of
patients without endoscopic CD recurrence after ileocecal
resection. Although the original paper of Rutgeerts et al4
looked at clinical recurrence during follow-up in this sub-
group, data about hospitalization, intra-abdominal bowel
damage, and the need for endoscopic balloon dilatation or
redo-surgery were lacking. The POCER trial suggested that
early endoscopic remission does not preclude the need for
long-term monitoring,6 but it remains unclear whether all
patients in endoscopic remission after ileocecal resection
necessitate tight follow-up, and for how long. Although risk
factors for early postoperative CD recurrence are well
established,11,12 no data exist about potential risk factors
for late postoperative CD recurrence.
In this retrospective, multicenter study, we aimed to
evaluate the risk of late postoperative CD recurrenceFLA 5.6.0 DTD  YJCGH57237_proof according to a composite endpoint, in patients who are
initially in endoscopic remission after ileocecal resection.
Secondary goals were to compare the time to late post-
operative CD recurrence according to Rutgeerts score at
baseline endoscopy, to identify potential risk factors associ-
ated with late postoperative CD recurrence, and to evaluate
the risk of mucosal disease progression based on endoscopy,
fecal biomarker, and magnetic resonance imaging (MRI).
Materials and Methods
Study Aims
The risk of late postoperative CD recurrence was
evaluated through a retrospective cohort study in 3
large-volume IBD centers in France (Nancy University
Hospital, Nancy) and Belgium (Liège University Hospital,
Liège and Imelda General Hospital, Bonheiden).
Patient Selection
All CD patients that underwent an ileocecal resection
with curative intent between September 2006 and
September 2016 were screened for eligibility in the
participating centers. Only patients with absence of
endoscopic signs of recurrence (defined as Rutgeerts
score i0 or i1) at the ileocolonic anastomosis during
baseline assessment were included. Baseline assessment
was defined as the first endoscopy after surgery, taking
place after month 3 but before the end of month 18
following ileocecal resection. Patients that underwent an
ileocecal resection without curative intent, patients with
an ileostomy, and patients younger than 18 years of age
at the time of surgery were excluded from analysis.
Data Collection
Baseline characteristics were recorded at the moment
of baseline endoscopy performed after month 3 and before
the end of month 18 following ileocecal resection, and
included age, sex, disease duration, age at diagnosis,25 July 2020  6:14 pm  ce OB
What You Need to Know
Background
Approximately half of patients with Crohn’s disease
(CD) require surgery in the first decade after diag-
nosis. Risk factors for early recurrence of CD after
surgery are well established, but little is known
about the risk of later recurrence.
Findings
Among patients with CD treated by ileocecal resec-
tion, 40% of patients had a late recurrence, despite
initial endoscopic remission, after a median follow-
up time of 3.5 years. No individual risk factors for
late postoperative recurrence of CD or mucosal dis-
ease progression could be identified.











































































307Montreal disease classification, smoking status, and previ-
ous surgery. Treatment courses with an immunomodulator
(methotrexate, thiopurine, 6-mercaptopurine) or biological
therapy (infliximab, adalimumab, certolizumab, vedolizu-
mab, ustekinumab) between date of diagnosis and surgery,
between surgery and baseline endoscopy, and until the end
of follow-up, were registered. New or worsening IBD-
related abdominal pain or diarrhea, IBD-related hospitali-
zation, occurrence of new intra-abdominal fistulae, ab-
scesses or strictures, the need for endoscopic balloon
dilatation of the anastomosis, and the need to repeat the
surgery were recorded during follow-up after baseline
endoscopy, including the time of first event. Furthermore,
results of all endoscopic assessments, fecal calprotectin
levels, and MRI examinations after baseline were collected.
End of follow-up was defined as the moment of the last
follow-up visit or if redo ileocecal resection was performed.Table 1. Baseline Characteristics at the Time of Endoscopy
Characteristic Total (N ¼ 86)
Age, y 38.4 (28.8–51.0)
Male 31 (36)
Disease duration, y 7.1 (1.7–20.0)
Age at diagnosis
A1: <16 y 4 (4.7)
A2: 16–40 y 68 (79.1)
A3: >40 y 14 (16.3)
Disease location
L1: ileal 56 (65.1)
L2: colonic 2 (2.3)
L3: ileocolonic 28 (32.6)
Associated upper digestive tract involvement 2 (2.3)
Disease behavior
B1: inflammatory 4 (4.7)
B2: stricturing 47 (54.7)
B3: penetrating 35 (40.7)
Perianal disease 21 (24.4)
Active smoking 27 (31.4)
Previous surgery 17 (19.8)
Treatment with IMM and/or biological between time
of diagnosis and ileocecal resection
None 31 (36)
IMM 49 (57)
Anti-TNF (infliximab, adalimumab, certolizumab) 39 (45.3)
Vedolizumab 4 (4.7)
Ustekinumab 1 (1.2)
Treatment with IMM and/or biological between











Values are median (interquartile range) or n (%).
IMM, immunomodulator; IQR, interquartile range; TNF, tumor necrosis factor
Implications for patient care
Time to recurrence of CD after resection exceeds 1
year after baseline endoscopy showing endoscopic
response, so patients should be carefully monitored
for more than 18 months after surgery.










































Primary aim was to evaluate the risk of late post-
operative CD recurrence, which was defined as a com-
posite endpoint of at least 1 of the following during
follow-up after baseline endoscopy: clinical recurrence
(ie, new or worsening IBD-related abdominal pain or
diarrhea), IBD-related hospitalization, occurrence of
bowel damage (ie, new intra-abdominal fistulae, ab-
scesses, or strictures), the need for endoscopic balloon
dilatation of the anastomosis, and the need to repeat the
surgery. Secondary aims were to (1) compare the time to
late postoperative CD recurrence according to Rutgeerts
score at baseline endoscopy, (2) to identify potential risk
factors associated with late postoperative CD recurrence,
and (3) to evaluate the risk of mucosal disease pro-
gression as defined by a composite mucosal endpoint of
at least 1 of the following: endoscopic disease progres-
sion (ie, evolution to Rutgeerts score > i1), elevation of
fecal biomarker (ie, fecal calprotectin level >250mg/g),
and disease activity on MRI (ie, segmental Nancy score at
the neoterminal ileum >2).
Statistical Analysis
Categorical variables were described as numbers and
percentages, and continuous variables as mean  SD or
median and interquartile range (IQR), depending on their
distribution. Pearson’s chi-square test was used for univar-
iate analysis involving categorical variables. Kaplan-Meier
curves were used for intergroup comparisons of time to
late postoperative CD recurrence. Univariate Cox regression
analyseswere used to identify potential risk factors for time-
dependent late postoperative CD recurrence. Variables with25 July 2020  6:14 pm  ce OB
Table 2. Crude Rate of Late Postoperative CD Recurrence
Outcome Measure Yes No
Clinical recurrence 31 (36) 55 (64)
IBD-related hospitalization 13 (15.1) 73 (84.9)
Need for endoscopic balloon dilatation 4 (4.7) 82 (95.3)
New intra-abdominal bowel damage 14 (16.3) 72 (83.7)
Need to repeat surgery 3 (3.5) 83 (86.5)
Composite endpoint 35 (40.7) 51 (59.3)
Values are n (%).
CD, Crohn’s disease; IBD, inflammatory bowel disease













































































425a P value <.1 in the univariate analysis were candidates for
the multivariate Cox model. The threshold for statistical
significance was set at a P value<.05 in all tests. The
statistical analysis was carried out using SAS software
(version 9.4; SAS Institute, Inc., Cary, NC). All authors had
























Out of a total number of 438 CD patients under-
going an ileocecal resection during the study period,
86 patients (n ¼ 55 women; n ¼ 27 active smokers)
could be included. Main reasons for exclusion were
Rutgeerts score i2 at postoperative endoscopy and
the lack of endoscopy within the prespecified time
interval. Median time between CD diagnosis and ileo-
cecal resection was 6.1 (IQR, 0.9–19.4) years. Seven-
teen (19.8%) patients had undergone previous
surgery, while the majority (n ¼ 55, 64%) had received
treatment with immunomodulators or biologicals
before ileocecal resection. Median time between sur-
gery and baseline endoscopy was 7.0 (IQR, 5.7–9.5)
months and 40 (46.5%) patients received medical
prophylaxis with immunomodulators or biologicals in
this period (Table 1).FLA 5.6.0 DTD  YJCGH57237_proof Late Postoperative Crohn’s Disease
Recurrence
Median follow-up time after baseline endoscopy was
3.5 (IQR, 1.5–5.3) years. Based on the composite
endpoint, late postoperative CD recurrence in the overall
population was seen in 35 (40.7%) patients (Table 2).
Recurrence status was comparable between patients
with Rutgeerts score i0 (n ¼ 20 of 55) or i1 (n ¼ 15 of
31) at baseline endoscopy (P ¼ .28), and independent
whether or not patients had received medical prophy-
laxis between surgery and baseline endoscopy (16 of 40
with prophylactic therapy vs. 19 of 46 without prophy-
lactic therapy; P ¼ .90; Figure 1).
Time to Recurrence
Among the 35 patients with late postoperative CD
recurrence, median time from baseline endoscopy to
disease recurrence was 14.2 (IQR, 6.3–26.2) months. The
proportion of patients with recurrence in the first year
and first 3 years of follow-up was 17.4% (n ¼ 15 of 86)
and 36% (n ¼ 31 of 86), respectively (Table 3). Kaplan-
Meier analysis indicated no statistically significant dif-
ferences between patients with Rutgeerts score i0 and
those with Rutgeerts score i1 at baseline endoscopy (P ¼
.11) (Figure 2). The survival analyses for each of the
individual components of the composite endpoint are
shown in Supplementary Figure 1.
Among the 16 patients with late postoperative CD
recurrence who received medical prophylaxis between
ileocecal resection and baseline endoscopy, median time to
disease recurrence was 19.4 (IQR, 9.1–25.8) months. In the
19 patients with late postoperative CD recurrence that did
not receive medical prophylaxis between ileocecal resec-
tion and baseline endoscopy, median time to disease
recurrence was 11.0 (IQR, 5.9–30.5) months. Kaplan-Meier
analysis indicated no difference in time to disease recur-
rence between patients who did or did not receive medical
prophylaxis between ileocecal resection and baseline
endoscopy (P ¼ .39) (Supplementary Figure 2).Figure 1. Late post-
operative CD recurrence in





































Table 3. Postoperative CD Recurrence Events Over Time (in the Total Population and Stratified by Prophylactic Treatment and
Rutgeerts Score at Baseline) (N ¼ 86)
Time Window
0–1 1–2 2–3 3–4 4–5 5–6 6–7 7–8 8–9
Events 15 10 6 2 1 1 0 0 0
Censored 13 8 8 3 8 4 4 1 2
At risk 58 40 26 21 12 7 3 2 0
Rutgeerts score at baseline
Prophylactic treatment: yes
i0 (n ¼ 28)
Events 3 3 1 1 0 1 0
Censored 2 2 4 3 6 1 1
At risk 23 18 13 9 3 1 0
i1 (n ¼ 12)
Events 2 3 2 0 0 0 0
Censored 1 0 2 0 1 0 1
At risk 9 6 2 2 1 1 0
Prophylactic treatment: no
i0 (n ¼ 27)
Events 3 3 3 1 1 0 0 0 0
Censored 8 2 0 0 1 2 0 1 2
At risk 16 11 8 7 5 3 3 2 0
i1 (n ¼ 19)
Events 7 1 0 0 0 0 0
Censored 2 4 2 0 0 1 2













































































































No risk factor for late postoperative CD recurrence
could be identified after univariate Cox regression
analysis in the overall population, although there was
a trend toward a higher risk for recurrence in patients
with Rutgeerts score i1 at baseline compared withFigure 2. Time to CD
recurrence after baseline
endoscopy based on the
composite endpoint in pa-
tients after ileocecal
resection.
FLA 5.6.0 DTD  YJCGH57237_proof patients with Rutgeerts score i0 (hazard ratio, 1.71;
95% confidence interval, 0.87–3.35; P ¼ .12)
(Table 4). In the separate groups of patients that did
and did not receive medical prophylaxis between
ileocecal resection and baseline endoscopy, no risk
factors could be identified either (Supplementary
























Table 4. Factors Associated With Late Postoperative CD Recurrence in the Overall Population
Risk Factor N
Recurrence Univariate Regression
N HR 95% CI P Value
Gender .11a
Female 55 26 1
Male 31 9 0.54 0.25–1.15
Smoking status .22a
Inactive 59 21 1
Active 27 14 1.53 0.78–3.03
Age at diagnosisb 86 35 1.00 0.98–1.03 .74a
Age at surgeryb 86 35 0.99 0.97–1.02 .58a
Disease location .94a
L1 56 21 1
L2 2 0 0 N/A
L3 28 14 1.13 0.57–2.23
Disease behavior .55a
B1 4 2 1
B2 47 21 0.84 0.19–3.63
B3 35 12 0.58 0.13–2.63
Perianal disease .66a
No 65 33 1
Yes 21 2 0.84 0.38–1.85
Previous surgery .22a
No 69 27 1
Yes 17 8 1.62 0.75–3.48
Previous IMM and/or biological treatment .53a
No 32 12 1
Yes 54 23 1.25 0.62–2.52
Baseline endoscopy .12a
Rutgeerts score i0 55 20 1
Rutgeerts score i1 31 15 1.71 0.87–3.35
IMM and/or biological treatment between
surgery and baseline endoscopy
.39a
No 46 19 1
Yes 40 16 0.75 0.38–1.45
CI, confidence interval; HR, hazard ratio; IMM, immunomodulator; N/A, not applicable.
a Q5.
bHR of quantitative variables reflects the risk variation for 1-unit increase of the variable.





















































































































In 71 of 86 patients, at least 1 objective measurement
of mucosal inflammatory activity (endoscopy, fecal cal-
protectin, MRI) was available during follow-up. Based on
a composite mucosal endpoint, disease progression was
seen in 29 of 71 (40.8%) patients (Supplementary
Table 3). Prevalence of mucosal disease progression
during follow-up was comparable between patients with
Rutgeerts score i0 (n ¼ 19 of 48) and Rutgeerts score i1
(n ¼ 10 of 23) at baseline endoscopy (P ¼ .75), and in-
dependent whether or not patients had received medical
prophylaxis between surgery and baseline endoscopy
(13 of 35 with prophylactic therapy vs 16 of 36 without
prophylactic therapy; P ¼ .53).
Among the 29 patients with mucosal disease progres-
sion, median time from baseline endoscopy to progression
was 24.1 (IQR, 13.5–38.4) months. Kaplan-Meier analysis
indicated no difference between patients with Rutgeerts
score i0 and those with Rutgeerts score i1 at baseline
endoscopy (P ¼ .44). We could not identify any risk factorFLA 5.6.0 DTD  YJCGH57237_proof for mucosal disease progression in the subgroup of pa-
tients with available data (Supplementary Table 4).Discussion
This is the first study specifically looking at the risk of
late postoperative recurrence in CD patients who are
initially in endoscopic remission after ileocecal resection,
and this by using a composite endpoint. With a median
follow-up time of 3.5 years after baseline endoscopy, CD
recurrence was seen in up to 40% of patients, and
occurred more than 1 year after baseline endoscopy in
the majority of those.
The POCER trial previously showed that patients with
endoscopic remission (Rutgeerts score i0 or i1) 6 months
after ileocecal resection are still at risk for endoscopic
recurrence 1 year later, with progression seen in 41% of
patients.6 Our data show a very similar risk of late post-
operative CD recurrence while using a different endpoint,
including not only clinical but also more objective25 July 2020  6:14 pm  ce OB
Q4 Q8




















































































































812parameters such as intra-abdominal bowel damage and
the need for balloon dilatation or redo surgery. Moreover,
because our study recorded the time to disease recurrence
since baseline endoscopy, which adds to the time since
surgery, it is clear that relevant CD relapse can still occur
even beyond 18 months after ileocecal resection. Long-
term tight monitoring of postoperative CD patients
regardless of their endoscopic appearance at index colo-
noscopy remains therefore warranted.
Risk factors for early postoperative CD recurrence
are well examined and include smoking, prior intesti-
nal surgery, absence of prophylactic treatment, pene-
trating disease at index surgery, and perianal disease
location.13,14 We could not confirm any of these as
specific risk factors for late postoperative recurrence.
Although active smoking and prior intestinal surgery
were more frequently associated with disease relapse,
hazard ratios did not reach statistical significance. This
could be due to a lack of statistical power; however,
risk factors for early and late postoperative CD
recurrence potentially differ. Indeed, the established
risk factors for early disease recurrence might not be
independent and only reflect disease severity or
complicated disease course, making them correlate
less with late disease recurrence. Prospective data in
larger cohorts are needed to clarify this.
Most clinical algorithms support the use of pro-
phylactic therapy in patients with a high risk of early
postoperative CD recurrence, with step-up therapy in
all patients if endoscopic recurrence is seen at colo-
noscopy.15,16 Mainly anti–tumor necrosis factor ther-
apy, alone or in combination with other treatment
modalities, has shown to reduce endoscopic post-
operative CD recurrence,17 which has a predictive
value for symptomatic recurrence and the need for
future resection.4,18 The heterogeneity of our cohort,
including both patients that did and did not receive
medical prophylaxis immediately after surgery, makes
it difficult to estimate if recurrence rates reflect ‘true’
late postoperative recurrence or merely represent
loss of response to the treatment. Nevertheless, crude
recurrence rates were comparable in patients with
and without prophylactic treatment between ileocecal
resection and baseline endoscopy, and immunomod-
ulators and biological therapy in the immediate
postoperative period did not decrease the risk of late
disease recurrence. Our composite primary endpoint,
however, did not include endoscopic progression
given the lack of systematic endoscopic follow-up in
this retrospective cohort. Taken into account that
most (n ¼ 31 of 35) patients experiencing a relapse
were symptomatic, this was in line with data from the
prospective PREVENT trial, in which infliximab
treatment only reduced endoscopic but not clinical
recurrence.19
A recent paper of Rivière et al20 showed that pa-
tients initiating medical prophylaxis immediately after
surgery more often had Rutgeerts score i1 at firstFLA 5.6.0 DTD  YJCGH57237_proof endoscopic evaluation. In the follow-up of their cohort,
patients with Rutgeerts score >i1 experienced more
frequently postoperative CD recurrence (both clinical
as judged by the need to repeat the surgery) than pa-
tients with Rutgeerts score i1, a finding that
remained unmodified when excluding the patients that
initiated immediate postoperative prophylaxis.20
However, the initiation of immunomodulators or
anti–tumor necrosis factor therapy in patients with an
asymptomatic endoscopic recurrence reflected by
Rutgeerts score i2 did not lead to improved out-
comes.20 The true value of postoperative medication in
asymptomatic patients after surgery remains thus
uncertain. In this regard, it would have been inter-
esting to study the effect of postoperative medical
prophylaxis on bowel damage alone, but the relative
low number of events withheld us from performing
this specific subanalysis. Future studies on late post-
operative CD recurrence should be conducted in larger
cohorts, including more centers or using nationwide
databases.
Mucosal disease progression, based on a composite
secondary endpoint of endoscopy, fecal biomarker and
MRI, was seen in 41% of patients. As this was a retro-
spective study with no standardized protocol during
follow-up, data about mucosal disease activity were only
available in a subgroup (n ¼ 71) of patients, and might
therefore suffer a selection bias. Indeed, patients with a
clinical suspicion of disease relapse were more likely to
undergo additional investigation with endoscopy, fecal
calprotectin, or MRI.
Strengths of this study are its multicenter design
and long follow-up time. In contrast to the initial
cohort of Rutgeerts, data were registered in the bio-
logic era and primary endpoint included objective
parameters on top of clinical recurrence. Limitations
are its retrospective design, and the relative low
number of patients eligible for inclusion despite a large
initial cohort of more than 400 patients that under-
went ileocecal resection during the study period. This
was partly explained by the lack of timely post-
operative endoscopic evaluation in a subset of patients
in which colonoscopy was often replaced by dosage of
fecal calprotectin or MRI, thereby reflecting real-world
practice and patients’ preferences in the participating
centers. Last, the time frame of which postoperative
endoscopy assessment was eligible for inclusion was
rather broad, potentially introducing a selection bias.
Nevertheless, median time between surgery and
baseline endoscopy was 7 months, with a narrow
interquartile range (3.8 months), so the impact on the
outcomes was estimated as low.
In conclusion, late postoperative CD recurrence was
seen in up to 40% of patients despite initial endoscopic
remission. Tight monitoring of these patients is recom-
mended beyond 18 months after ileocecal resection.
Prospective studies in large sets of patients are needed
to clarify the specific risk factors for late postoperative25 July 2020  6:14 pm  ce OB




























































872CD recurrence, including the effect of prophylactic ther-








Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
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Supplementary Figure 1. (A–E) Time to Crohn’s disease recurrence after baseline endoscopy for the individual components of
the composite endpoint in patients after ileocecal resection with curative intent. UIABD, (previously) unknown intra-abdominal
(bowel) damage. RS, Rutgeerts score.
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Figure 2. Time to Crohn’s
disease recurrence after
baseline endoscopy based
on the composite endpoint












Supplementary Table 1. Factors Associated With Late Postoperative CD Recurrence in the Patients That Received Medical
Prophylaxis Between Ileocecal Resection and Baseline Endoscopy
Risk Factor N Recurrence
Univariate Regression
HR 95% CI P Value
Sex .12a
Female 29 14 1
Male 11 2 0.31 0.07–1.36
Smoking status .11a
Inactive 27 8 1
Active 13 8 2.23 0.83–5.95
Age at diagnosisb 40 16 0.99 0.94–1.05 .79a
Age at surgeryb 40 16 0.99 0.95–1.04 .71a
Disease location .31a
L1 18 5 1
L2 2 0 0.60 0.02–12.79
L3 20 11 2.12 0.72–6.22
Disease behavior .43a
B1 2 0 1
B2 19 10 2.68 0.13–54.15
B3 19 6 1.41 0.06–29.62
Perianal disease .93a
No 24 10 1
Yes 16 6 1.05 0.37–2.95
Previous surgery .44a
No 30 11 1




No 6 2 1
Yes 34 14 1.43 0.32–6.32
Baseline endoscopy .13a
Rutgeerts score i0 28 9 1
Rutgeerts score i1 12 7 2.16 0.80–5.83
CI, confidence interval; HR, hazard ratio; IMM, immunomodulator.
bHR of quantitative variables reflects the risk variation for 1-unit increase of the variable.
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Supplementary Table 2. Factors Associated With Late Postoperative CD Recurrence in the Patients Without Medical
Prophylaxis Between Ileocecal Resection and Baseline Endoscopy
Risk Factor n Recurrence
Univariate Regression
HR 95% CI P Value
Sex .35a
Female 26 12 1
Male 20 7 0.64 0.25–1.63
Smoking status .83a
Inactive 32 13 1
Active 14 6 1.11 0.42–2.95
Age at diagnosisb 46 19 1.01 0.98–1.04 .72a
Age at surgeryb 46 19 0.99 0.97–1.02 .65a
Disease location .47a
L1 38 16 1
L2 0 N/A N/A NA
L3 8 3 0.64 0.18–2.20
Disease behavior .35a
B1 2 2 1
B2 28 11 0.33 0.07–1.55
B3 16 6 0.33 0.06–1.69
Perianal disease .85a
No 41 17 1
Yes 5 2 0.87 0.20–3.76
Previous surgery
No 39 15 1 .27a
Yes 7 4 1.87 0.62–5.65
Previous IMM and/or biological treatment .31a
No 26 10 1
Yes 20 9 1.61 0.65–4.00
Baseline endoscopy .57a
Rutgeerts score i0 27 11 1
Rutgeerts score i1 19 8 1.31 0.52–3.27
CI, confidence interval; HR: hazard ratio; IMM: immunomodulator; N/A: not applicable.
a Q6.
bHR of quantitative variables reflects the risk variation for 1-unit increase of the variable.
Supplementary Table 3. Crude Rate of Late Mucosal
Disease Progression
Outcome Measure Yes No
Endoscopic progression (n ¼ 42) 18 (42.9) 24 (57.1)
Elevated fecal calprotectin (n ¼ 37) 12 (32.4) 25 (67.6)
MRI disease activity (n ¼ 40) 8 (20.0) 32 (80.0)
Composite mucosal endpoint (n ¼ 71)a 29 (40.8) 42 (59.2)
Values are n (%).
MRI, magnetic resonance imaging
aTotal number of patients with at least 1 of the following: endoscopy, fecal
calprotectin, MRI.
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Supplementary Table 4. Factors Associated With Mucosal Disease Progression in the Subgroup of Patients With Available
Data (n ¼ 71)
Risk Factor n Recurrence
Univariate Regression
HR 95% CI P Value
Sex .71a
Female 46 20 1
Male 25 9 0.86 0.39–1.89
Smoking status .18a
Inactive 48 18 1
Active 23 11 1.69 0.79–3.61
Age at diagnosisb 71 29 1.00 0.97–1.03 .85a
Age at surgeryb 71 29 1.00 0.97–1.02 .73a
Disease location .66a
L1 46 18 1
L2 2 0 0.34 0.01–6.12
L3 23 11 1.20 0.56–2.56
Disease behavior .18a
B1 3 2 1
B2 39 19 0.79 0.18–3.39
B3 29 8 0.37 0.08–1.77
Perianal disease .29a
No 55 21 1
Yes 16 8 1.57 0.69–3.57
Previous surgery .53a
No 58 22 1
Yes 13 7 1.31 0.56–3.08
Previous IMM and/or biological treatment .78a
No 28 10 1
Yes 43 19 1.11 0.52–2.40
Baseline endoscopy .45a
Rutgeerts score i0 48 19 1
Rutgeerts score i1 23 10 1.35 0.62–2.94
IMM and/or biological treatment between surgery
and baseline endoscopy
.59a
No 36 16 1
Yes 35 13 0.82 0.39–1.71
CI, confidence interval; HR, hazard ratio; IMM, immunomodulator; N/A, not applicable.
a Q7.
bHR of quantitative variables reflects the risk variation for one unit increase of the variable
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